The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Zacks.com on MSN
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
The FINANCIAL — Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus everolimus in previously-treated patients ...
Opdivo and Yervoy combination improves median OS to 23.7 months versus 20.6 months with Lenvima or Nexavar in uHCC patients. The combination shows a higher overall response rate of 36% compared to 13% ...
Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, ...
Well, good afternoon once again. Welcome to TD Cowen's 45th Annual Healthcare Conference. We're delighted to have Bristol-Myers Squibb with us again this year. Representing the company is Adam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results